SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-264329
Filing Date
2023-10-27
Accepted
2023-10-26 21:53:28
Documents
7
Period of Report
2023-11-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A d520772ddef14a.htm DEF 14A 1095360
2 GRAPHIC g520772dsp038.jpg GRAPHIC 125665
3 GRAPHIC g520772dsp039.jpg GRAPHIC 124151
4 GRAPHIC g520772g00a02.jpg GRAPHIC 55749
5 GRAPHIC g520772g01n59.jpg GRAPHIC 104005
6 GRAPHIC g520772g02n59.jpg GRAPHIC 105564
7 GRAPHIC g520772g04o29.jpg GRAPHIC 96528
  Complete submission text file 0001193125-23-264329.txt   1928197
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 231351785
SIC: 2834 Pharmaceutical Preparations